These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17503411)

  • 1. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
    Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
    J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.
    Oka T; Ouchida M; Koyama M; Ogama Y; Takada S; Nakatani Y; Tanaka T; Yoshino T; Hayashi K; Ohara N; Kondo E; Takahashi K; Tsuchiyama J; Tanimoto M; Shimizu K; Akagi T
    Cancer Res; 2002 Nov; 62(22):6390-4. PubMed ID: 12438221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
    Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
    J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
    Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
    Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential display analysis of mRNAs in chronic myelogenous leukaemia.
    el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM
    East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of FHIT expression in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
    Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
    Goh HG; Hwang JY; Kim SH; Lee YH; Kim YL; Kim DW
    Transl Res; 2006 Nov; 148(5):249-56. PubMed ID: 17145570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXA9 gene expression in the chronic myeloid leukemia progression.
    Tedeschi FA; Zalazar FE
    Leuk Res; 2006 Nov; 30(11):1453-6. PubMed ID: 16630659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
    Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
    Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
    Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
    Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
    Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T
    Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.